Dibenzoylmorphine

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

<templatestyles src="Module:Hatnote/styles.css"></templatestyles>

Dibenzoylmorphine
Dibenzoylmorphine.png
Systematic (IUPAC) name
3,6-dibenzoyl-(5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan
Clinical data
Legal status
  • Illegal under UN drug conventions as "ester of morphine"
Chemical data
Formula C31H27NO5
Molecular mass 493.549 g/mol
  • C7CC24C3C=CC(OC(=O)c6ccccc6)C2Oc1c4c(CC3N7C)ccc1OC(=O)c5ccccc5
  (verify)

Dibenzoylmorphine is an opiate analogue that is a derivative of morphine. It was developed in the early 1900s after first having been synthesised in 1875 in the UK by the CR Alders Wright organisation at Bayer, along with various other esters of morphine, but was never used medically, instead being widely sold as one of the first "designer drugs" for around five years following the introduction of the first international restrictions on the sale of heroin in 1925. It is described as being virtually identical to heroin and morphine in its effects, and consequently was itself banned internationally in 1930 by the Health Committee of the League of Nations, in order to prevent its sale as an unscheduled alternative to diacetylmorphine.[1]

It is produced in the same fashion as other esters of morphine -- treating morphine with an acid anhydride (or some acids or other relatives of acids like acetyl chloride) to get a mono-, di-, tri-, or tetra-ester. Specifically, the original 1875 synthesis was effected by boiling morphine for 2 hours in benzoic acid at 130°C, as was heroin made by using acetic anhydride.

See also

References



<templatestyles src="Asbox/styles.css"></templatestyles>